60 Degrees Pharmaceuticals, Inc. (SXTP) Cash Flow Statement
Where SXTP’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$6.8M
- Capital expenditures
- $218,084 21.7% of revenue
- Free cash flow
- −$7.1M −702.9% margin
- Returned to shareholders
- —
- Change in cash
- −$149,288 cash at year-end $1.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
SXTP operating cash flow, capex and free cash flow
SXTP cash flow trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$167,2992020 | −$6.8M2025 | — | |
| Capital expenditures | $70,9782020 | $218,0842025 | +25.2%/yr | |
| Free cash flow | −$238,2772020 | −$7.1M2025 | — | |
| Free cash flow margin | −10.9%2020 | −702.9%2025 | −691.9 pts | |
| Stock-based compensation | $02022 | $456,3442025 | — | |
| Capex / revenue | 3.3%2020 | 21.7%2025 | +18.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SXTP cash flow by activity
SXTP net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
SXTP cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$7.4M | −$8.0M | −$3.8M | −$6.2M | −$4.3M | −$3.0M |
| Depreciation & amortization | $82,872 | $63,745 | $100,372 | $78,786 | $71,785 | $27,865 |
| Stock-based compensation | $456,344 | $3.6M | $1.5M | $0 | — | — |
| Change in working capital | −$5,501 | $192,724 | $405,364 | $3.3M | $2.9M | $2.4M |
| Other non-cash items | −$14,412 | −$1.6M | −$2.8M | $1.8M | $642,917 | $425,742 |
| Cash from operating activities | −$6.8M | −$5.6M | −$4.5M | −$1.0M | −$649,106 | −$167,299 |
| Investing activities | ||||||
| Capital expenditures | −$218,084 | −$181,114 | −$115,888 | −$60,133 | −$35,392 | −$70,978 |
| Investments (net) | $473,000 | −$1.9M | −$107,971 | −$60,133 | −$35,392 | −$70,978 |
| Acquisitions & other investing | $0 | $181,114 | $107,971 | $60,133 | $35,392 | $70,978 |
| Cash from investing activities | $254,916 | −$1.9M | −$115,888 | −$60,133 | −$35,392 | −$70,978 |
| Financing activities | ||||||
| Net borrowing (repayment) | — | $0 | −$961,111 | $1.1M | $611,226 | $611,226 |
| Shares issued | $6.5M | $7.0M | $6.5M | $0 | $0 | $0 |
| Other financing | −$15,196 | $10,963 | $981,351 | $116,706 | $0 | −$333,869 |
| Cash from financing activities | $6.4M | $7.1M | $6.5M | $1.2M | $611,226 | $277,357 |
| Summary | ||||||
| Net change in cash | −$149,288 | −$483,132 | $1.9M | $149,466 | −$76,303 | −$95,174 |
| Cash at end of period | $1.5M | $1.7M | $2.1M | $264,865 | $115,399 | $191,702 |
| Free cash flow | −$7.1M | −$5.8M | −$4.7M | −$1.1M | −$684,498 | −$238,277 |
| Free cash flow margin | −702.9% | −959.4% | −1,837.3% | −479.4% | −59.0% | −10.9% |
| Capex / revenue | 21.7% | 29.8% | 45.7% | 26.9% | 3.1% | 3.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$2.3M | −$2.1M | −$1.4M | −$2.3M | −$1.7M | −$1.9M | −$2.0M | −$2.2M | −$4.2M | $430,470 | −$2.0M | $4.2M |
| Depreciation & amortization | $30,811 | $25,865 | $23,567 | $22,830 | $19,678 | $16,797 | $15,947 | $14,659 | $11,008 | $22,131 | $23,444 | $25,434 |
| Stock-based compensation | $2,400 | $124,102 | $111,961 | $167,235 | −$186,763 | $186,763 | $61,639 | $668,974 | −$125,368 | $125,368 | $852,698 | $393,266 |
| Change in working capital | −$101,016 | −$554,261 | $26,613 | −$159,651 | $46,057 | $81,480 | $218,929 | −$263,990 | $221,238 | $16,547 | $1.3M | −$2.5M |
| Other non-cash items | $98,058 | −$247,110 | −$415,539 | $175,608 | $387,384 | −$5,105 | $114,192 | $59,634 | $2.9M | −$1.7M | −$290,237 | −$5.8M |
| Cash from operating activities | −$2.2M | −$2.7M | −$1.7M | −$2.1M | −$1.5M | −$1.6M | −$1.6M | −$1.7M | −$1.2M | −$1.1M | −$63,667 | −$3.8M |
| Investing activities | ||||||||||||
| Capital expenditures | −$30,000 | −$30,000 | −$135,431 | −$9,998 | −$47,322 | −$5,482 | −$2,098 | −$38,643 | −$130,559 | −$9,814 | −$66,562 | −$1,826 |
| Investments (net) | $0 | $1.2M | −$1.2M | −$25,487 | −$51,684 | $1.7M | −$2,098 | −$1.7M | −$130,559 | −$9,814 | −$66,562 | −$27,907 |
| Acquisitions & other investing | −$55,984 | −$11,440 | $0 | $9,998 | $47,322 | $5,482 | $2,098 | $38,643 | $130,559 | $9,814 | — | $1,826 |
| Cash from investing activities | −$85,984 | $1.2M | −$1.4M | −$25,487 | −$51,684 | $1.7M | −$2,098 | −$1.7M | −$130,559 | −$9,814 | — | −$27,907 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | — | −$150,420 | — | — |
| Net borrowing (repayment) | — | — | — | — | — | — | $0 | $0 | — | — | — | — |
| Shares issued | $0 | $3.4M | $458,614 | $4.3M | $0 | $1.7M | $0 | $5.2M | $16,217 | $1.9M | $0 | $6.5M |
| Other financing | $0 | $0 | $0 | $878 | $0 | −$16,074 | $973 | −$80,000 | −$17,082 | $139,198 | −$1 | −$483,216 |
| Cash from financing activities | $0 | $3.4M | $458,614 | $4.3M | $0 | $1.7M | $973 | $5.2M | −$865 | $1.9M | −$1 | $6.0M |
| Summary | ||||||||||||
| Net change in cash | −$2.3M | $1.8M | −$2.6M | $2.1M | −$1.5M | $1.8M | −$1.6M | $1.7M | −$1.3M | $752,215 | −$76,055 | $2.2M |
| Cash at end of period | $1.0M | $3.3M | $1.5M | $4.1M | $2.0M | $3.5M | $1.7M | $3.3M | $1.6M | $2.9M | $2.1M | $2.2M |
| Free cash flow | −$2.2M | −$2.8M | −$1.8M | −$2.1M | −$1.5M | −$1.6M | −$1.6M | −$1.7M | −$1.3M | −$1.2M | −$130,229 | −$3.8M |
| Free cash flow margin | −1,073.5% | −1,709.9% | −602.5% | −484.2% | −1,483.6% | −980.0% | −627.4% | −1,271.2% | −1,055.3% | −1,088.5% | −304.9% | −7,335.5% |
| Capex / revenue | 14.4% | 18.5% | 44.6% | 2.3% | 46.9% | 3.4% | 0.8% | 28.6% | 104.5% | 9.3% | 155.9% | 3.6% |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | — | −2.65 | — | −0.90 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
SXTP cash generation
In fiscal 2025 (ended December 31, 2025), 60 Degrees Pharmaceuticals generated -$6.8 million of cash from operations and spent $0.2 million on capital expenditures, leaving free cash flow of -$7.1 million, −702.9% of revenue. Cash and equivalents fell by $0.1 million over the year.
Related: SXTP income statement, SXTP balance sheet. See the SXTP stock overview for the latest quote and news.
SXTP cash flow FAQ
What is 60 Degrees Pharmaceuticals's free cash flow?
60 Degrees Pharmaceuticals's free cash flow was -$7.1 million in fiscal 2025: -$6.8 million of operating cash flow minus $0.2 million of capital expenditures It was -$5.8 million a year earlier..
How much cash does 60 Degrees Pharmaceuticals generate from operations?
60 Degrees Pharmaceuticals generated -$6.8 million of cash from operating activities in fiscal 2025.
How much does 60 Degrees Pharmaceuticals spend on capital expenditures?
60 Degrees Pharmaceuticals spent $0.2 million on capital expenditures in fiscal 2025, 21.7% of revenue, compared with $0.2 million the year before.